Nancy J Nelson. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » AnimalsAntineoplastic Agents/pharmacologyAntineoplastic Agents/therapeutic useCelecoxibClinical Trials as TopicCyclooxygenase 2Cyclooxygenase Inhibitors/pharmacologyCyclooxygenase Inhibitors/therapeutic useErbB Receptors/antagonists & inhibitorsErlotinib HydrochlorideHumansMembrane Proteins/antagonists & inhibitorsMouth Neoplasms/metabolismMouth Neoplasms/prevention & controlProtein Kinase Inhibitors/pharmacologyProtein Kinase Inhibitors/therapeutic usePyrazoles/pharmacologyPyrazoles/therapeutic useQuinazolines/pharmacologyQuinazolines/therapeutic useReceptor Cross-Talk/drug effectsSignal Transduction/drug effectsSulfonamides/pharmacologySulfonamides/therapeutic use
Substances: See more » Antineoplastic AgentsCyclooxygenase InhibitorsMembrane ProteinsProtein Kinase InhibitorsPyrazolesQuinazolinesSulfonamidesErlotinib HydrochlorideCyclooxygenase 2PTGS2 protein, humanErbB ReceptorsCelecoxib
Year: 2006 PMID: 16418508 DOI: 10.1093/jnci/djj044
Source DB: PubMed Journal: J Natl Cancer Inst ISSN: 0027-8874 Impact factor: 13.506